Validation of the Functional Assessment of Cancer Therapy-Lung Symptom Index-12 (FLSI-12)

Lung Cancer

Volumn 57, Issue 3, 2007, Pages 339-347

  Eton, David T ^a,b   Cella, David ^a,b   Yount, Susan E ^a,b   Davis, Kimberly M ^c  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

Author keywords

FACT; FLSI 12; Lung cancer; Minimally important difference; Patient reported outcome; Quality of life; Symptoms; Validity

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER THERAPY; CLINICAL FEATURE; CONCURRENT VALIDITY; CORRELATION FUNCTION; CRONBACH ALPHA COEFFICIENT; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INTERNAL CONSISTENCY; LUNG; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PERFORMANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOMETRY; QUALITY OF LIFE; RATING SCALE; RELIABILITY; SELF REPORT; SYMPTOM; VALIDATION STUDY;

AGED; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 34548104676     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.03.021     Document Type: Article

References (27)

1. Center for Drug Evaluation and Research. Draft guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. Rockville, MD: US Food and Drug Administration; February 2006.
2. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
3. Bergman B., Aaronson N.K., Ahmedzai S., Kaasa S., and Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 30A (1994) 635-642
4. Cella D., Tulsky D.S., Gray G., et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11 (1993) 570-579
5. Cella D.F., Bonomi A.E., Lloyd S.R., Tulsky D.S., Kaplan E., and Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12 (1995) 199-220
6. Bottomley A., Efficace F., Thomas R., Vanvoorden V., and Ahmedzai S.H. Health-related quality of life in non-small-cell lung cancer: methodologic issues in randomized controlled trials. J Clin Oncol 21 (2003) 2982-2992
7. Butt Z., Webster K., Eisenstein A.R., et al. Quality of life in lung cancer: the validity and cross-cultural applicability of the Functional Assessment of Cancer Therapy-Lung scale. Hematol Oncol Clin N Am 19 (2005) 389-420
8. Eton D.T., Yost K.J., and Cella D. Future trends in patient reported outcomes assessment for patients with advanced-stage lung cancer receiving targeted therapy. Clin Lung Cancer 8 (2006) 99-109
9. Hollen P.J., Gralla R.J., Kris M.G., et al. Measurement of quality of life in patients with lung cancer in multi-center trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 73 (1994) 2087-2098
10. Cella D., Eton D.T., Fairclough D.L., et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 55 (2002) 285-295
11. Cella D., Paul D., Yount S., et al. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest 21 (2003) 526-535
12. Zubrod C.G., Schneiderman M., Frei E., et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosporamide. J Chron Dis 11 (1960) 7-33
13. Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system-version 4 (1997), Center on Outcomes, Research & Education (CORE), Evanston Northwestern Healthcare, Evanston, IL
14. Yost K.J., and Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Evaluat Health Profess 28 (2005) 172-191
15. Wyrwich K., Tierney W., and Wolinsky F. Further evidence supporting a SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 52 (1999) 861-873
16. Hays R.D., and Fayers P. Evaluating multi-item scales. In: Fayers P., and Hays R.D. (Eds). Assessing quality of life in clinical trials: methods and practice (2005), Oxford, New York 41-53
17. Cohen J. A power primer. Psychol Bull 112 (1992) 155-159
18. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21 (2003) 2237-2246
19. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
20. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
21. Spigel D.R., Hainsworth J.D., Burkett E.R., et al. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial. Clin Lung Cancer 7 (2005) 127-132
22. Cella D., Herbst R.S., Lynch T.J., et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 23 (2005) 2946-2954
23. Eton D.T., Fairclough D.L., Cella D., Yount S.E., Bonomi P., and Johnson D.H. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group study 5592. J Clin Oncol 21 (2003) 1536-1543
24. Efficace F., Bottomley A., Smit E.F., et al. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 17 (2006) 1698-1704
25. Langendijk H., Aaronson N., de Jong J., ten Velde G., Muller M., and Wouters M. The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol 55 (2000) 19-25
26. Maione P., Perrone F., Gallo C., et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian Lung Cancer in the Elderly study. J Clin Oncol 23 (2005) 6865-6872
27. Chang C.-H., Cella D., Masters G.A., et al. Real-time clinical application of quality-of-life assessment in advanced lung cancer. Clin Lung Cancer 4 (2002) 104-109